Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8964356 | 0.95 | ALDH1A1 (0.50) | MAPTALDH1A1RAB9AESR1MEN1 | |
| SCHEMBL8964352 | 0.95 | ALDH1A1 (0.50) | MAPTALDH1A1RAB9AESR1MEN1 | |
| SCHEMBL13607636 | 0.88 | ALDH1A1 (0.56) | MAPTALDH1A1RAB9AESR1MEN1 | |
| SCHEMBL8964517 | 0.88 | ALDH1A1 (0.47) | MAPTALDH1A1RAB9AESR1MEN1 | |
| SCHEMBL8964444 | 0.88 | ALDH1A1 (0.47) | MAPTALDH1A1RAB9AESR1MEN1 | |
| SCHEMBL8964491 | 0.84 | ALDH1A1 (0.47) | MAPTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL8964487 | 0.84 | ALDH1A1 (0.47) | MAPTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL8964466 | 0.82 | ALDH1A1 (0.49) | MAPTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL453575 | 0.82 | ALDH1A1 (0.49) | MAPTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL453576 | 0.82 | ALDH1A1 (0.49) | MAPTALDH1A1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616169-A2 | CHROMATOGRAPHY MEMBRANES FOR THE PURIFICATION OF CHIRAL COMPOUNDS | Natrix Separations Inc. (CA) | 2013-07-24 | — | — | EP | claimed |
| WO-2012037101-A2 | CHROMATOGRAPHY MEMBRANES FOR THE PURIFICATION OF CHIRAL COMPOUNDS | NATRIX SEPARATIONS INC. (CA) | 2012-03-22 | — | — | WO | claimed |
| US-20120064601-A1 | Chromatography Membranes for the Purification of Chiral Compounds | NATRIX SEPARATIONS INC. (CA) | 2012-03-15 | — | — | US | claimed |
| US-11919922-B2 | Bicyclic nucleosides and oligomers prepared therefrom | UNIVERSITAT BERN (CH) | 2024-03-05 | — | — | US | disclosed |
| WO-2023111597-A1 | THERAPEUTIC OLIGONUCLEOTIDES HAVING AN INTER-NUCLEOSIDE AMIDE LINKAGE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-06-22 | — | — | WO | disclosed |
| US-11028117-B2 | Bicyclic nucleosides and oligomers prepared therefrom | Universität Bern (CH) | 2021-06-08 | — | — | US | disclosed |
| EP-3790968-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | Alpha Anomeric SAS (FR) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215333-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2019-11-14 | — | — | WO | disclosed |
| US-20190345188-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | Universität Bern (CH) | 2019-11-14 | — | — | US | disclosed |
| EP-3548502-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | Universität Bern (CH) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018099946-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | Universität Bern (CH) | 2018-06-07 | — | — | WO | disclosed |
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-03-15 | — | — | US | disclosed |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHONOLOGICAL UNIVERSITY (SG) | 2011-10-06 | — | — | US | disclosed |
| WO-2010027326-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-03-11 | — | — | WO | disclosed |
| EP-1108724-B1 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | SIRNA THERAPEUTICS INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-6972330-B2 | Contacting N4-acetyl-5',3'-di-O-acetyl-2'-O- methyl cytidine with Lewis acid to form 2'-)-methyladenosine nucleoside which is converted to phosphoramidite | SIRNA THERAPEUTICS, INC. (US) | 2005-12-06 | — | — | US | disclosed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| EP-0270651-A4 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1989-03-29 | — | — | EP | disclosed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | MAPT 4315/4885ALDH1A1 4860/4885RAB9A 4172/4885 |
| US-11028117-B2 | Bicyclic nucleosides and oligomers prepared therefrom | RRM2, NUDT1, REV1 | MAPT 3154/4885ALDH1A1 2881/4885RAB9A 4364/4885 |
| US-20190345188-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | RRM2, PRPF31, SLC29A2 | MAPT 3217/4885ALDH1A1 2993/4885RAB9A 4295/4885 |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | MAPT 4315/4885ALDH1A1 4860/4885RAB9A 4172/4885 |
| US-11919922-B2 | Bicyclic nucleosides and oligomers prepared therefrom | RRM2, REV1, NUDT1 | MAPT 2899/4885ALDH1A1 2884/4885RAB9A 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.